280 related articles for article (PubMed ID: 24915530)
1. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
[TBL] [Abstract][Full Text] [Related]
4. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
[TBL] [Abstract][Full Text] [Related]
5. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
[TBL] [Abstract][Full Text] [Related]
7. The role of cognitive reserve in mediating HIV-associated neurocognitive disorders in older adults living with-treated HIV in Mbeya, Tanzania: A cross-sectional observational study.
M S; E K; N TR; E C; K S; Kaminyoge MS; B M; R W; G L; W K G; S-M P; B M
Int J Geriatr Psychiatry; 2023 Dec; 38(12):e6042. PubMed ID: 38141048
[TBL] [Abstract][Full Text] [Related]
8. Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men.
McDonnell J; Haddow L; Daskalopoulou M; Lampe F; Speakman A; Gilson R; Phillips A; Sherr L; Wayal S; Harrison J; Antinori A; Maruff P; Schembri A; Johnson M; Collins S; Rodger A;
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):120-7. PubMed ID: 24991974
[TBL] [Abstract][Full Text] [Related]
9. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
Cysique LA; Brew BJ
J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
[TBL] [Abstract][Full Text] [Related]
11. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
[TBL] [Abstract][Full Text] [Related]
12. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
[TBL] [Abstract][Full Text] [Related]
13. Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa.
Joska JA; Westgarth-Taylor J; Myer L; Hoare J; Thomas KG; Combrinck M; Paul RH; Stein DJ; Flisher AJ
AIDS Behav; 2011 Aug; 15(6):1197-203. PubMed ID: 20614176
[TBL] [Abstract][Full Text] [Related]
14. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
[TBL] [Abstract][Full Text] [Related]
15. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.
Grant I; Franklin DR; Deutsch R; Woods SP; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Smith DM; Heaton RK;
Neurology; 2014 Jun; 82(23):2055-62. PubMed ID: 24814848
[TBL] [Abstract][Full Text] [Related]
17. Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.
Kabuba N; Anitha Menon J; Franklin DR; Heaton RK; Hestad KA
AIDS Behav; 2017 Jun; 21(6):1717-1727. PubMed ID: 27278547
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon.
Njamnshi AK; Bissek AC; Ongolo-Zogo P; Tabah EN; Lekoubou AZ; Yepnjio FN; Fonsah JY; Kuate CT; Angwafor SA; Dema F; Njamnshi DM; Kouanfack C; Djientcheu Vde P; Muna WF; Kanmogne GD
J Neurol Sci; 2009 Oct; 285(1-2):149-53. PubMed ID: 19631349
[TBL] [Abstract][Full Text] [Related]
19. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.
Burdo TH; Weiffenbach A; Woods SP; Letendre S; Ellis RJ; Williams KC
AIDS; 2013 Jun; 27(9):1387-95. PubMed ID: 23435298
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.
Hulgan T; Samuels DC; Bush W; Ellis RJ; Letendre SL; Heaton RK; Franklin DR; Straub P; Murdock DG; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I; Kallianpur AR;
Clin Infect Dis; 2015 Nov; 61(9):1476-84. PubMed ID: 26129753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
